These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
35. Sequential therapies for Crohn's disease: optimizing conventional and biologic strategies. Desilva S; Kaplan G; Panaccione R Rev Gastroenterol Disord; 2008; 8(2):109-16. PubMed ID: 18641593 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease. Coteur G; Feagan B; Keininger DL; Kosinski M Aliment Pharmacol Ther; 2009 May; 29(9):1032-41. PubMed ID: 19222413 [TBL] [Abstract][Full Text] [Related]
37. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study. Feagan BG; Reilly MC; Gerlier L; Brabant Y; Brown M; Schreiber S Aliment Pharmacol Ther; 2010 Jun; 31(12):1276-85. PubMed ID: 20298497 [TBL] [Abstract][Full Text] [Related]
38. Drug approvals: '08 in review. Certolizumab pegol (Cimzia). Laustsen G; Carrillo F; Johnson J; Smith C Nurse Pract; 2009 Feb; 34(2):26-7. PubMed ID: 19155878 [No Abstract] [Full Text] [Related]
39. Recent advances in the management of Crohn's disease. Caprilli R; Angelucci E; Clemente V Dig Liver Dis; 2008 Sep; 40(9):709-16. PubMed ID: 18430617 [TBL] [Abstract][Full Text] [Related]
40. Drug evaluation: CNTO-1275, a mAb against IL-12/IL-23p40 for the potential treatment of inflammatory diseases. Wittig BM Curr Opin Investig Drugs; 2007 Nov; 8(11):947-54. PubMed ID: 17979029 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]